Melanoma Patients' samples could unlock personalized treatment clues

NCT ID NCT01205815

Recruiting now Knowledge-focused Sponsor: Vanderbilt-Ingram Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study collects and stores tissue and blood samples from up to 3,000 melanoma patients to understand the biological changes that drive the disease. Researchers will analyze the samples to identify molecular markers that may help doctors choose the most effective treatments. The goal is to speed up and improve the accuracy of treatment decisions for each patient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could help doctors choose more effective treatments for melanoma patients based on their tumor's molecular profile.
What could go wrong: This is an observational study focused on sample collection and analysis, not a treatment trial. It may not directly lead to new therapies or immediate benefits for participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

Vanderbitl-Ingram Cancer Center
RECRUITING

Nashville, Tennessee, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.